Researchers have identified the mechanism by which a specific genetic variant, HLA-DRB1*01:03, drives more aggressive inflammatory bowel disease (IBD) by triggering autoantibodies that neutralise interleukin-10, a key anti-inflammatory protein. The discovery, published after three decades of investigation, may enable earlier identification of high-risk patients and inform targeted treatment strategies for both Crohn’s disease and ulcerative colitis.
Background Context
Interleukin-10 (IL-10) functions as a critical regulator of inflammation in the gastrointestinal tract, helping to prevent excessive immune responses that damage intestinal tissue. The HLA-DRB1*01:03 genetic variant has been associated with severe IBD since the early 1990s, but the biological reason remained unclear. Patients carrying this variant have historically experienced more frequent flare-ups, greater need for surgical intervention, and reduced response to standard therapies. Understanding the link between this genetic marker and disease severity has been a long-standing goal in gastroenterology research.
Key Findings
The study team discovered that individuals carrying HLA-DRB1*01:03 are predisposed to produce autoantibodies that specifically target and neutralise IL-10. When these antibodies deactivate IL-10, the body loses a vital mechanism for controlling gut inflammation, leading to more aggressive disease courses. This finding was corroborated by a separate large-scale genetic analysis of more than 43,000 patients, which confirmed that combinations of variants within the HLA-DRB1 gene correlate with disease severity across both Crohn’s disease and ulcerative colitis. Patients with this genetic profile showed higher rates of surgical intervention and escalation to advanced therapies. The research provides a clear biological explanation for why a subset of IBD patients experience significantly worse outcomes, despite receiving similar initial treatments to those with milder disease.
Clinical Relevance
These findings open the possibility of genetic screening soon after diagnosis to identify patients at elevated risk of severe disease progression. Clinicians could use this information to consider earlier intervention with more potent therapies or closer monitoring protocols, potentially preventing irreversible bowel damage before it occurs. The genetic marker is present only in a subset of the IBD population, meaning it does not account for all cases of severe disease, but it offers a defined target for personalised management. The research moves the field closer to stratified care models, where treatment intensity is matched to biological risk rather than waiting for clinical deterioration.
Reference
ScienceAlert. Scientists solve a 30-year mystery behind inflammatory bowel disease. Available at: https://www.sciencealert.com/scientists-solve-a-30-year-mystery-behind-inflammatory-bowel-disease
Wellcome Sanger Institute. IBD patients with severe disease could be identified and treated earlier due to new genetic marker. Available at: https://www.sanger.ac.uk/news_item/ibd-patients-with-severe-disease-could-be-identified-and-treated-earlier-due-to-new-genetic-marker/
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.